Suppr超能文献

无心脏停搏显著停顿的抑制性心脏晕厥的电生理机制:治疗与预后意义。ELICA随机试验

ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause: Therapeutic and prognostic implications. The ELICA randomized trial.

作者信息

Sardu Celestino, Marfella Raffaele, Testa Gianluca, Santamaria Matteo, Sacra Cosimo, Ranauro Alfredo, Paolisso Giuseppe, Rizzo Maria Rosaria, Barbieri Michelangela

机构信息

Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples Department of Medicine and Health Sciences, University of Molise Cardiovascular and Arrhythmias Department, John Paul II Research and Care Foundation, Campobasso, Italy.

出版信息

Medicine (Baltimore). 2018 Aug;97(31):e11757. doi: 10.1097/MD.0000000000011757.

Abstract

BACKGROUND

The aim of this study was to investigate syncope recurrence in patients with a 2A cardioinhibitory response to the head up tilt testing (HUT).

METHODS

In this study, we enrolled 72 consecutive patients affected by syncope with cardioinhibitory response without asystolic significant pause to HUT (2A type). In these patients, we randomly performed electrophysiological study (ES). In case of sino-atrial node, atrio-ventricular node dysfunction, and sustained arrhythmias induction, the ES resulted positive. ES was positive in 9 patients (group A), then treated by catheter ablation, and/or by devices implants. Otherwise, ES resulted negative (group B), and these patients did not receive an interventional treatment. However, after ES, we evaluated syncope recurrence during 360 days follow-up.

RESULTS

There was a lower statistical significant syncope recurrence at follow-up, comparing group A to group B of patients [n of events 9 (40.9%) vs 8 (57.1%), P < .05]. At multivariate analysis, ES result was the only factor predicting syncope recurrence at follow-up (hazard ratio = 27.63, 95% confidence interval = 1.02-54.24, P < .005).

CONCLUSION

The positivity to ES study, and successful interventional therapies may reduce the burden of syncope recurrence at 360 days follow-up in 2A HUT subjects.Clinical trial number: NCT02861274.

摘要

背景

本研究旨在调查对直立倾斜试验(HUT)有2A型心脏抑制反应的患者晕厥复发情况。

方法

在本研究中,我们连续纳入了72例因晕厥且对HUT有心脏抑制反应且无心脏停搏显著间歇的患者(2A型)。在这些患者中,我们随机进行电生理研究(ES)。如果窦房结、房室结功能障碍以及诱发持续性心律失常,则ES结果为阳性。9例患者(A组)的ES结果为阳性,随后接受导管消融和/或植入装置治疗。否则,ES结果为阴性(B组),这些患者未接受介入治疗。然而,在ES后,我们评估了360天随访期间的晕厥复发情况。

结果

随访时,A组患者的晕厥复发率低于B组患者[事件数9例(40.9%)对8例(57.1%),P<0.05]。多因素分析显示,ES结果是预测随访期间晕厥复发的唯一因素(风险比=27.63,95%置信区间=1.02-54.24,P<0.005)。

结论

ES研究阳性及成功的介入治疗可能会减轻2A型HUT受试者360天随访时晕厥复发的负担。临床试验编号:NCT02861274。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e29c/6081146/a8032323bb5f/medi-97-e11757-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验